Testicular cancer in young norwegians

Publisher Website
Google Scholar
Abstract
The clinical experience is reviewed in 597 Norwegian testicular cancer patients (age range: 15–45 years) treated from 1979 to 1986. During this period, computer tomography, determination of serum AFP/HCG, and cisplatin‐based chemotherapy represented the modern diagnostic and therapeutic mcdalities. Before orchiectomy 67% of the patients had elevated AFP/HCG. An abnormal postorchiectomy serum tumour marker decrease and the presence of small vessel infiltration in the histological sections of the primary tumour significantly predicted microscopic retroperitoneal metastases in patients with clinical stage I (CSI) nonseminoma. One‐third of these patients had a pathological stage II (PSII). After radiotherapy 99% of 90 seminoma patients (CSI/IIa) survived for 5 years. After cisplatin‐based chemotherapy (+ radiotherapy/surgery) the 5‐year survival rate in 25 patients with advanced seminoma was 81 %. The survival rate in 148 nonseminoma patients PSI/IIa was 100% and 87% in 94 patients with advanced nonseminoma (≥CSIIb). Nausea, general exhaustion, myelosuppression, peripheral neuropathy, and Raynaud‐like phenomena were the main acute treatment‐related side effects. Slight gastrointestinal problems, slight peripheral neuropathy, Raynaud‐like phenomena, and fertility disturbances were frequent late side effects. The sexual life in testicular cancer patients did not seem to be significantly impaired as compared to the normal population. Most of the patients reported no or only slight emotional problems during and after treatment. The need of thorough information at the time of diagnosis was stressed by most of them.Secondary cancer was diagnosed in 27 of 795 patients (1970–1982) (Testicular: 15; pulmonary: 4; sarcoma: 2; others: 6).Testicular cancer is today a curable malignancy. Future clinical research has to concentrate on the identification of high‐risk and low‐risk patients, the avoidance of overtreatment, and the reduction of toxicity (especially of long‐term side effects).